Autoantibody production in anti-TNF-α-treated patients

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 319-329

  Alessandri, Cristiano ^a   Scrivo, Rossana ^a   Spinelli, Francesca Romana ^a   Ceccarelli, Fulvia ^a   Magrini, Leonardo ^a   Priori, Roberta ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoantibodies; Human antichimeric antibodies (HACA); Infliximab; Rheumatic inflammatory disorders

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CHIMERIC ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HERMES ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE; PREVALENCE; RADIOIMMUNOASSAY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

EID: 35748958740     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.034     Document Type: Conference Paper

References (64)

1. CHARLES, P.J., R.J. SMEENK, J. DE JONG, et al. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum. 43: 2383-2390.
2. DE RYCKE, L., E. KRUITHOF, N. VAN DAMME, et al. 2003. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 48: 1015-1023.
3. VERMEIRE, S., M. NOMAN, G. VAN ASSCHE, et al. 2003. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 32-39.
4. BOBBIO-PALLAVICINI, F., C. ALPINI, R. CAPORALI, et al. 2004. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6: R264-R272.
5. ERIKSSON, C., S. ENGSTRAND, K.-G. SUNDQVIST, et al. 2005. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann. Rheum. Dis. 64: 403-407.
6. FERRARO-PEYRET, C., F. COURY, J.G. TEBIB, et al. 2004. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res. Ther. 6: R535-R543.
7. FERRACCIOLI, G., F. MECCHIA, E. DI POI, et al. 2002. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann. Rheum. Dis. 61: 358-361.
8. ATZENI, F., P. SARZI-PUTTINI, D. DELL'ACQUA, et al. 2006. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther. 8: R3.
9. ALESSANDRI, C., M. BOMBARDIERI, N. PAPA, et al. 2004. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63: 1218-1221.
10. CHEN, H.A., K.C. LIN, C.H. CHEN, et al. 2006. The effect of etanercept on anticyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 35-39.
11. BENDTZEN, K., P. GEBOREK, M. SVENSON, et al. 2006. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor-inhibitor infliximab. Arthritis Rheum. 54: 3782-3789.
12. BENDER, N.K., C.E. HEILIG, B. DROLL, et al. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27: 269-274.
13. CARAMASCHI, P., D. BIASI, M. COLOMBATTI, et al. 2006. Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. 26: 209-214.
14. DE RYCKE, L., D. BAETEN, E. KRUITHOF, et al. 2005. Infliximab, but not etanercept, induces IgM anti-dsDNA antibodies as main antinuclear reactivity: biological and clinical implications in autoimmune arthritis. Arthritis Rheum. 52: 2192-2201.
15. BLANK, M., I. KRAUSE, M. FRIDKIN, et al. 2002. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest. 109: 797-804.
16. JONSDOTTIR, T., J. FORSLID, A.M. VAN VOLLENHOVEN, et al. 2004. Treatment with tumor necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. 63: 1075-1078.
17. VISVANATHAN, S., C. WAGNER, J. SMOLEN, et al. 2006. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum. 54: 2840-2844.
18. SELLAM, J., Y. ALLANORE, F. BATTEUX, et al. 2005. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. Joint Bone Spine 72: 48-52.
19. ALLANORE, Y., J. SELLAM, F. BATTEUX, et al. 2004. Induction of autoantibody in refractory rheumatoid arthritis patients treated by infliximab. Clin. Exp. Rheumatol. 22: 756-758.
20. MARCELLI, C., E. BOUCQUILLARD, J.L. SIAME, et al. 2005. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7: R545-R551.
21. BLEUMINK, G.S., E.J. TER BORG, C.G. RAMSELAAR, et al. 2001. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxf.) 40: 1317-1319.
22. FERRACCIOLI, G.F., R. ASSALONI & A. PERIN. 2002. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360: 645.
23. CAIRNS, A.P., M.K. DUNCAN, A.E. HINDER, et al. 2002. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann. Rheum. Dis. 61: 1031-1032.
24. MOHAN, A.K., E.T. EDWARDS, T.R. COTE, et al. 2002. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360: 646.
25. SHAKOOR, N., M. MICHALSKA, C.A. HARRIS, et al. 2002. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579-580.
26. ENAYATI, P.J. & K.A. PAPADAKIS. 2005. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J. Clin. Gastroenterol. 39: 303-306.
27. BERTHELOT, C.N., S.J. GEORGE & S. HSU. 2005. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J. Am. Acad. Dermatol. 53(Suppl. I): S260-S262.
28. BENSOUDA-GRIMALDI, L., D. MULLEMAN, J.P. VALAT, et al. 2007. Adalimumab-associated multiple sclerosis. J. Rheumatol. 34: 239-240.
29. KRAUSE, I., G. VALESINI, R. SCRIVO, et al. 2003. Autoimmune aspects of cytokine and anticytokine therapies. Am. J. Med. 115: 390-397.
30. PAPP, K.A. 2006. The long-term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res. 298: 7-15.
31. KARY, S., M. WORM, H. AUDRING, et al. 2006. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann. Rheum. Dis. 65: 405-407.
32. SFIKAKIS, P.P., A. ILIOPOULOS, A. ELEZOGLOU, et al. 2005. Psoriasis induced by antitumor necrosis factor therapy. A paradoxical adverse reaction. Arthritis Rheum. 52: 2513-2518.
33. MATTHEWS, C., S. ROGERS & O. FITZGERALD. 2006. Development of new-onset psoriasis while on anti-TNFα treatment. Ann. Rheum. Dis. 65: 1529-1530.
34. BERG, E.L., T. YOSHINO, L.S. ROTT, et al. 1991. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cellleukocyte adhesion molecule 1. J. Exp. Med. 174: 1461-1466.
35. FLIER, J., D.M. BOORSMA, P.J. VAN BEEK, et al. 2001. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 194: 398-405.
36. BRAUN, J., X. BARALIAKOS, J. LISTING, et al. 2005. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52: 2447-2451.
37. SHARMA, S.M., A.V. RAMANAN, P. RILEY, et al. 2006. Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease. Ann. Rheum. Dis. Published online 14 Dec 2006 [doi:10.1136/ard. 2006 065441].
38. BIESTER, S., C. DEUTER, H. MICHELS, et al. 2006. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91: 319-324.
39. REDDY, A.R. & O.C. BACKHOUSE. 2003. Does etanercept induce uveitis? Br. J. Ophthalmol. 87: 925.
40. VON ANDRIAN, U.H. & C.R. MACKAY. 2000. T-cell function and migration: two sides of the same coin. N. Engl. J. Med. 343: 1020-1034.
41. GERMANO V., A. PICCHIANTI DIAMANTI, G. BACCANO, et al. 2005. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann. Rheum. Dis. 64: 1519-1520.
42. LAZARUS, M.N. & D.A. ISENBERG. 2005. Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome. Ann. Rheum. Dis. 64: 1062-1064.
43. MCDONAGH, J.E. & D.A. ISENBERG. 2000. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 59: 230-232.
44. WEINBLATT, M.E., E.C. KEYSTONE, D.E. FURST, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum. 48: 35-45.
45. FURST, D.E., M.H. SCHIFF, R.M. FLEISCHMANN, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30: 2563-2571.
46. GARCIA-PLANELLA, E., E. DOMENECH, M. ESTEVE-COMAS, et al. 2003. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur. J. Gastroenterol. Hepatol. 15: 351-354.
47. PITTONI, V. & G. VALESINI. 2002. The clearance of apoptotic cells: implications for autoimmunity. Autoimmun. Rev. 1: 154-161.
48. HART, S.P., G.J. DOUGHERTY, C. HASLETT, et al. 1997. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J. Immunol. 159: 919-925.
49. GEWERZ, H., Z. XIAO-HUI & T.F. LINT. 1995. Structure and function of pentraxins. Curr. Opin. Immunol. 7: 54-64.
50. BICKERSTAFF, M.C., M. BOTTO, W.L. HUTCHINSON, et al. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5: 694-697.
51. VIA, C.S., A. SHUSTOV, V. RUS, et al. 2001. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167: 6821-6826.
52. DE RYCKE, L., X. VERHELST, E. KRUITHOF, et al. 2005. Rheumatoid factor, but not anti-citrullinated protein antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann. Rheum. Dis. 64: 299-302.
53. CARAMASCHI, P., D. BIASI, E. TONOLLI, et al. 2005. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol. Int. 26: 58-62.
54. BRAUN-MOSCOVICI, Y., D. MARKOVISTS, O. ZINDER, et al. 2006. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J. Rheumatol. 33: 497-500.
55. SMEETS, T.J., M.C. KRAAN, M.E. VANL OON, et al. 2003. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 48: 2155-2162.
56. YAZDANI-BIUKI, B., E. STADLMAIER, A. MULABECIROVIC, et al. 2005. Blockade of tumour necrosis factor alpha significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64: 1224-1226.
57. BOBBIO-PALLAVICINI, F., R. CAPORALI, C. ALPINI, et al. 2006. High IgA rheumatoid factor levels are associated with poor clinical response to TNFα inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 66: 302-307.
58. BAERT, F., M. NOMAN, S. VERMEIRE, et al. 2003. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608.
59. FARRELL, R.J., M. ALSAHLI, Y.T. JEEN, et al. 2003. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124: 917-924.
60. AYBAY, C., S. OZEL & C. AYBAY. 2006. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol. Int. 26: 473-480.
61. MAINI, R.N., E.W. ST CLAIR, F.C. BREEDVELD, et al. 1999. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
62. HARAOUI, B., L. CAMERON, M. OUELLET, et al. 2006. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33: 31-36.
63. VAN DE PUTTE, L.B.A., C. ATKINS, M. MALAISE, et al. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63: 508-516.
64. KLARESKOG, L., J. WAJDULA, P. YEH, et al. 2005. Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes following 5 years of treatment with Enbrel® in patients with rheumatoid arthritis. Arthritis Rheum. 52(Suppl.): S348.